Genesis Therapeutics, a startup using artificial intelligence to design small molecule drugs, has raised $200 million in Series B financing — one of the largest rounds for an AI-focused biotech this year.
The round is being co-led by Andreessen Horowitz (a16z) Bio + Health and an anonymous life science…
Click here to view original post
